January 28, 2022 – 12th Annual California ALS Research Summit

The session entitled Guamanian ALS Parkinson's Dementia Complex was co-chaired by Dr. Richard Smith and his colleague Dr. Jeffery Kelly, co-chairman of the Department of Molecular Medicine at Scripps Research.

The following presentations were included in this session:

• The Vanishing Incidence of ALS-PD on Guam: Current Implications (Ralph Garruto, PhD, Binghamton University)

• From Guam to ALS Therapy (Paul Cox, PhD, Director of the Institute for Ethnomedicine)

• The Emerging Role of Misfolded Synuclein Prions in Initiation and Progression of Neurodegenerative Diseases (Russ Lebovitz, MD, PhD, CEO of Amprion Inc.)

Click here to view the full Summit schedule.

November 12, 2021 – 16th Annual Peggy and Gary Edwards Distinguished ALS Lecture

Neurotherapeutics in the Era of Translational Medicine Speaker: Richard A. Smith, M.D.

Director, Center for Neurologic Study

La Jolla, California

Friday, November 12, 12:00 p.m. to 1:00 p.m. CDT

Event Link: https://houstonmethodist.webex.com/houstonmethodist/j.php?MTID=macfa79ed611475ed2194b23edfc383d9

• Access code: 2530 124 9830

• Meeting password: MaFEGCwm653

July 26, 2021 – Tau Antisense Drug Trial: Phase 1b Results

Biogen and Ionis announced that BIIB080/IONIS-MAPTRx, an antisense drug, demonstrated robust time and dose-dependent lowering of tau protein in cerebrospinal fluid (CSF) over the three-month treatment period and sustained reductions during the six-month post-treatment period. Click here to learn more.